MA5-14929

antibody from Invitrogen Antibodies

Targeting: BTK AGMX1, ATK, IMD1, PSCTK1, XLA

Western blot (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA5-14929

Provider

Invitrogen Antibodies

Product name

Btk Monoclonal Antibody (E.127.9)

Antibody type

Monoclonal

Antigen

Synthetic peptide

Description

It is not recommended to aliquot this antibody.

Antibody clone number

E.127.9

Concentration

85 µg/mL

References

Submitted references

Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection.

Byun JY, Koh YT, Jang SY, Witcher JW, Chan JR, Pustilnik A, Daniels MJ, Kim YH, Suh KH, Linnik MD, Lee YM
Scientific reports 2021 Sep 21;11(1):18671

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of Btk in extracts from Ramos and Raji cells using Btk monoclonal antibody (Product # MA5-14929).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 5 Pharmacologic inhibition of BTK and its correlation with efficacy. ( A , B ) Whole blood was collected from the CIA-induced rats at the 0, 4, 12, 24 h after final drug administration, and then PBMCs and plasma were isolated. BTK phosphorylation was detected by immunoblotting and normalized to the total BTK level, and BTK occupancy was measured by ELISA using a biotinylated probe as described in the Materials and Methods. The concentration of poseltinib in the plasma was below the LLOQ at 4 h after administration. Full-length blots are presented in Supplementary Fig. 1 . ( C ) Correlations between drug efficacy (clinical arthritis score) and the PD markers BTK phosphorylation percentage (left)/drug efficacy and BTK occupancy percentage (right). Linear regression was performed by using GraphPad Prism 6. The data are presented as the mean +- S.D.